The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

Table 3 Subgroup analyses of PFS in bTMB high and bTMB low NSCLC patients

Variable	No. 0f cohorts	No. of patients	bTMB high			bTMB low
Variable	No. 0f cohorts	bTMB high/bTMB low	Pooled HR (95% CI)	P	I² (%)	Pooled HR (95% CI)	P	I² (%)
Line of therapy
1	5	528/1271	0.51 (0.37–0.70)	< 0.01	50.5	0.96 (0.66–1.39)	0.83	85.4
≥ 2	2	221/573	0.63 (0.47–0.84)	< 0.01	0	1.01 (0.84–1.20)	0.94	0
Therapy regimen
Anti-PD-L1 vs CT	4	455/1269	0.65 (0.53–0.80)	< 0.01	0	1.05 (0.93–1.19)	0.4	0
Anti-PD-L1 plus anti-CTLA-4 vs CT	1	134/389	0.53 (0.34–0.82)	< 0.01	N/A	1.55 (1.23–1.95)	< 0.01	N/A
Anti-PD-1 plus CT vs CT	2	160/186	0.34 (0.22–0.51)	< 0.01	0	0.52 (0.36–0.74)	< 0.01	0
Type of NGS panel
Foundation one	3	308/875	0.61 (0.47–0.78)	< 0.01	0	1.00 (0.87–1.16)	0.95	0
Gardant OMNI	3	379/920	0.53 (0.34–0.83)	< 0.01	67	0.99 (0.57–1.73)	0.99	92
OncoScreen Plus	1	62/49	0.30 (0.13–0.68)	< 0.01	N/A	0.63 (0.25–1.60)	0.33	N/A
PD-L1 expression
Unselected for PD-L1	6	662/1542	0.54 (0.42–0.70)	< 0.01	44.6	0.99 (0.74–1.32)	0.93	82.2
PD-L1 positive	1	87/302	0.55 (0.33–0.92)	0.02	N/A	1.00 (0.78–1.29)	1.00	N/A
Cut-off value (mut/meg)
16	3	308/875	0.61 (0.47–0.78)	< 0.01	0	1.00 (0.87–1.16)	0.95	0
Others	4	441/969	0.49 (0.32–0.74)	< 0.01	62.8	0.93 (0.56–1.54)	0.77	88.7

mut/meg mutation/mergbase, N/A not applicable, 95% CI 95% confidence interval, HR hazard ratio, PFS progression free survival

ISSN: 1471-2407